David Zaccardelli Sells 110,456 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 110,456 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28. Following the transaction, the chief executive officer now directly owns 14,894,464 shares of the company’s stock, valued at $65,237,752.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Price Performance

Shares of VRNA stock opened at $34.93 on Thursday. The firm has a fifty day simple moving average of $29.69 and a 200-day simple moving average of $21.26. The company has a market capitalization of $2.79 billion, a PE ratio of -45.36 and a beta of 0.44. Verona Pharma plc has a twelve month low of $11.39 and a twelve month high of $35.62. The company has a current ratio of 8.61, a quick ratio of 8.61 and a debt-to-equity ratio of 0.72.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same quarter in the prior year, the firm earned ($0.11) EPS. Equities research analysts anticipate that Verona Pharma plc will post -2.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRNA has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of Verona Pharma in a research note on Tuesday, October 1st. Canaccord Genuity Group lifted their price target on shares of Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. Truist Financial raised their target price on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company started coverage on shares of Verona Pharma in a research report on Thursday, October 3rd. They set an “overweight” rating and a $50.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $39.33.

Institutional Investors Weigh In On Verona Pharma

A number of hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Verona Pharma by 25.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after buying an additional 529 shares in the last quarter. Values First Advisors Inc. acquired a new position in shares of Verona Pharma in the 3rd quarter worth approximately $494,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Verona Pharma by 14.9% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 155,835 shares of the company’s stock worth $4,483,000 after purchasing an additional 20,206 shares during the period. Claro Advisors LLC acquired a new position in shares of Verona Pharma in the 3rd quarter valued at about $209,000. Finally, GAMMA Investing LLC lifted its holdings in Verona Pharma by 70.6% in the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock worth $38,000 after acquiring an additional 553 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.